Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...

Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts.

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.

Report projects market growth but investors remain in cautious recovery mode LONDON – [7 January 2026] – Evaluate, the leading provider of market insights for the pharmaceutical industry, today ...

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 ...

Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Merck (MRK) is back in focus after a trio of recent developments, including an upcoming J.P. Morgan Healthcare Conference ...